高血小板反应性患者支架辅助栓塞术:三联与改良双联抗血小板治疗随机对照试验
这项前瞻性随机试验纳入高血小板反应性(HTPR)并接受支架辅助弹簧圈栓塞的未破裂颅内动脉瘤患者,1:1 随机接受三联抗血小板(加用西洛他唑)或改良双联抗血小板(氯吡格雷换为低剂量普拉格雷)治疗。主要终点为 90 天内所有出血事件,两组在 ITT 和 PP 人群中均无显著差异,血栓栓塞事件率亦无差异;MDAT 组 P2Y12 反应单位(PRU)随时间下降更明显,尤其负荷后 PRU。
要点
- HTPR 患者支架辅助栓塞后,三联与改良双联抗血小板 90 天出血风险无显著差异。
- 两组血栓栓塞事件率在 ITT 和 PP 分析中均无显著差异。
- 改良双联组 PRU 值随时间下降更明显,尤其负荷后 PRU。
核心结论
- 在 HTPR 并接受支架辅助弹簧圈栓塞的未破裂颅内动脉瘤患者中,三联抗血小板与改良双联抗血小板在 90 天随访期间所有出血事件和血栓栓塞事件风险无显著差异。
研究设计与样本
- 前瞻性随机临床试验,HTPR 患者按 1:1 随机分配至三联抗血小板组(加用西洛他唑)或改良双联抗血小板组(氯吡格雷换为低剂量普拉格雷)。
- 共 198 例参与者随机分组,其中 172 例维持初始抗血小板治疗 90 天;进行 ITT 和 PP 分析。
主要发现
- 与三联抗血小板组相比,改良双联抗血小板组 PRU 值随时间大幅下降,尤其负荷后 PRU。
临床怎么用
- 对于 HTPR 的未破裂颅内动脉瘤支架辅助栓塞患者,三联抗血小板与改良双联抗血小板在 90 天出血及血栓栓塞风险上未见显著差异,选择时可结合 PRU 下降需求个体化考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Modified antiplatelet therapies in patients with high on-treatment platelet reactivity (HTPR) remains unknown in neurointerventional treatment. We aimed to compare the safety and effectiveness of two different modified antiplatelet therapies in patients with HTPR undergoing stent-assisted coil embolization for an unruptured intracranial aneurysm. METHODS: We conducted a prospective, randomized clinical trial. Participants with HTPR were randomly assigned (1:1) to the triple antiplatelet therapy (TAT, addition of cilostazol) or modified dual antiplatelet therapy (MDAT, switched from clopidogrel to low-dose prasugrel) group. The primary outcome was all-bleeding-events during the 90-day follow-up period. The secondary outcomes were thromboembolic events and changes in the P2Y12 reaction unit (PRU) value throughout the follow-up period. Intention-to-treat (ITT) and per-protocol (PP) analyses were performed. RESULTS: In total, 172 of the 198 participants maintained initial antiplatelet therapy for 90 days. There was no significant difference in the all-bleeding-event rate between the two groups, both in the ITT population (hazard ratio [HR], 0.77 [95% CI, 0.49-1.20]; P = .26) and the PP population (HR, 0.79 [95% CI, 0.50-1.30]; P = .34). The thromboembolic event rate did not differ between the 2 groups in either the ITT population (HR, 0.33 [95% CI, 0.03-3.20]; P = .34) or the PP population (HR, 0.42 [95% CI, 0.04-4.70]; P = .48). Compared with those in the TAT group, the PRU values in the MDAT group greatly decreased over time, particularly for PRU after loading. CONCLUSION: Among patients with HTPR who underwent stent-assisted coil embolization for an unruptured intracranial aneurysm, there was no significant difference between the TAT and MDAT groups regarding the risk of all bleeding events and thromboembolic events during the 90 days of follow-up.
引用
- Ban SP, Kwon OK, Kim YD, et al. Comparison of Triple Antiplatelet (Aspirin, Clopidogrel, and Cilostazol) and Modified Dual Antiplatelet (Aspirin and Low-Dose Prasugrel) Therapy in Patients With High On-Treatment Platelet Reactivity Undergoing Stent-Assisted Coil Embolization for an Unruptured Intracranial Aneurysm: A Prospective Randomized Clinical Trial. Neurosurgery. 2025. PMID: 41070954. doi:10.1227/neu.0000000000003791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。